Prescription Required.Why?
A sodium-glucose co-transporter 2 (sglt2) inhibitor that helps your kidneys remove excess sugar from your blood into your urine.
A biguanide that lowers blood sugar by decreasing glucose production in the liver and improving insulin sensitivity.
A dipeptidyl peptidase-4 (dpp-4) inhibitor that increases the levels of incretin hormones, which help your body release more insulin when needed and reduce the amount of sugar your liver produces.
Treatment of type 2 diabetes mellitus in adults inadequately controlled with metformin and sitagliptin alone or other oral antidiabetic agents.
This triple combination medication works through three different mechanisms to lower blood sugar levels. Dapagliflozin increases glucose excretion in the urine, metformin reduces glucose production and improves insulin sensitivity, and sitagliptin enhances incretin action, leading to improved insulin secretion and reduced glucose production.
Store at room temperature, away from moisture and direct sunlight. Keep out of reach of children.
Dosage should be determined by your doctor based on your individual needs and response to treatment.
Follow your doctor's instructions carefully. Do not change your dose without consulting your doctor.
Hypoglycemia (low blood sugar)
Urinary tract infections
Genital yeast infections
Nausea
Vomiting
Diarrhea
Constipation
Headache
Dizziness
Fatigue
Weight loss
Limit alcohol intake, as it can increase the risk of hypoglycemia.
May cause dizziness or fatigue. Avoid driving or operating machinery if affected.
Not recommended during pregnancy or breastfeeding. Consult your doctor.
Not approved for use in children.
Use with caution in patients with kidney impairment. Dosage adjustment may be necessary.
Use with caution in patients with liver impairment. Dosage adjustment may be necessary.
Please consult your physician or pharmacist for detailed prescribing information and references specific to this drug combination.
